|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||23.6995 - 23.7228|
|52 Week Range||22.8500 - 26.0300|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.80%|
Half-Year Report on DBV Technologies Liquidity Contract with Natixis. Under the liquidity contract between DBV TECHNOLOGIES and NATIXIS, the following assets appeared on the liquidity account as of December ...
DBV Technologies to Present at the 36 th Annual J.P. DBV Technologies today announced that it will present at the 36 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:00 ...
DBV Technologies CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Recognized for His Lasting Impact on the Food Allergy Community and Research Advancement by FARE. DBV Technologies- Chief Executive ...
DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association. Primary endpoint of Phase IIb study ...
DBV Technologies Reports September 30, 2017 Cash Position. DBV Technologies today announced its cash and cash equivalents as of September 30, 2017.. Cash and cash equivalents as of September 30, 2017, ...
May 22, 2017 Dennis Gartman is editor and publisher of The Gartman Letter, and strategic advisor of the AdvisorShares Gartman Currency Hedged Gold ETFs (GEUR & GYEN). He regularly contributes to AlphaBaskets and lends his institutional insight to ...